VYNE

VYNE TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 35.8 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.0.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-22

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-22 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-22

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $3.25

Why

Momentum36 · Δ7d -

Value41 · Δ7d -0.0

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

-17.7

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 35.8 / Value 41.1

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$38.38M

Beta

2.02

Shares Out

42.99M

P/E (TTM) · Derived

-1.4

P/S (TTM)

35.88

P/FCF (TTM) · Derived

-1.42

Rev YoY

-57.4%

EPS YoY

-58.5%

Gross Margin

+94.9%

Op Margin

-7118.5%

Net Debt

-$29.01M

Current Ratio

20.86

As of 2026-07-22 • Updated nightlySource: Internal modelMethodology